Commerzbank and ODDO BHF's Annual Corporate Conference
6 September 2022
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Commerzbank and ODDO BHF's Annual Corporate Conference, 6 September 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 2 |
Company Overview 02 03 04
Agenda
02 | 03 | 04 | |
Business Update | Financials Q2/22 | Attachments | |
Q2/22 | & Outlook | ||
Commerzbank and ODDO BHF's Annual Corporate Conference, 6 September 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 3 |
Company Overview 02 03 04
Our Purpose and Mission
Ever better medicine for ever
more people
We improve people's lives by providing high
quality and affordable healthcare
Commerzbank and ODDO BHF's Annual Corporate Conference, 6 September 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 4 |
Company Overview 02 03 04
A Global Leader in Health Care Products and Services
in sales (FY/2021)
€ 37.5 bn
Global presence in 100+
countries
Leading market
#1 positions
Long-term opportunities in growing, non-cyclicalmarkets
100 +
Employees
worldwide
(as of June 30, 2022)
300,000+
Strong financial performance and cash flow generation
Commerzbank and ODDO BHF's Annual Corporate Conference, 6 September 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 06 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 September 2022 09:39:01 UTC.